Australia markets close in 1 hour 48 minutes

BiomX Inc. (PHGE-UN)

NYSE American - Nasdaq Real-time price. Currency in USD
Add to watchlist
6.120.00 (0.00%)
At close: 3:44PM EDT

BiomX Inc.

7 Pinhas Sapir Street
2nd Floor
Ness Ziona 7414002
972 7 2394 2377

Full-time employees:Β 95

Key executives

NameTitlePayExercisedYear born
Mr. Jonathan Eitan Solomon MBACEO & Director564.25kN/A1977
Dr. Sailaja PuttaguntaChief Medical Officer562.25kN/A1969
Dr. Merav Bassan Ph.D.Chief Devel. Officer410.87kN/A1966
Prof. Rotem Sorek Ph.D.Scientific FounderN/AN/AN/A
Dr. Eran ElinavScientific FounderN/AN/AN/A
Dr. Timothy K. LuScientific FounderN/AN/AN/A
Ms. Marina WolfsonSr. VP of Fin. & Operations and Sec.N/AN/A1984
Ms. Noel KurdiVP of Investor Relations & StrategyN/AN/AN/A
Ms. Inbal Benjamini-ElranVP of HRN/AN/AN/A
Mr. Assaf OronChief Bus. OfficerN/AN/A1974
Amounts are as of 31 December 2020, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


BiomX Inc., a clinical-stage microbiome company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), primary sclerosing cholangitis (PSC), cystic fibrosis (CF), atopic dermatitis, and colorectal cancer (CRC). The company's lead product candidate BX001, which is in Phase II that helps to modify the appearance of skin in various skin types, including oily and acne-prone skin type. Its products under development include BX003 to treat acne-prone skin, IBD, and PSC; BX004, a therapeutic phage product candidate for chronic respiratory infections caused by pseudomonas aeruginosa; and BX005, a topical phage product candidate for staphylococcus aureus, a bacterium associated with the development and exacerbation of inflammation in atopic dermatitis, as well as CRC program targets strains of bacteria found in CRC tumors. The company has license agreement with Keio University and JSR Corporation to bacterial targets that are related to IBD and the phage to eradicate these bacterial targets. BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel.

Corporate governance

BiomX Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.